← Eichor
Study identifier: NCT05378841 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Efficacy of Surgical Joint Denervation in Painful Digital Osteoarthritis

Condition: Osteoarthritis Hand  ·  Sponsor: Assistance Publique - Hôpitaux de Paris

PhaseNA
Planned participants19
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Digital osteoarthritis is the second localization of symptomatic osteoarthritis, after the knee. Its cardinal symptoms are particularly intense pain and functional impairment in the case of the erosive form. There is currently no etiological treatment for osteoarthritis. Symptomatic treatments have a modest efficacy, which justifies the search for new treatments. The surgical options are arthrodesis or prosthesis, invasive techniques potentially sources of complications, and finally proposed infrequently given the prevalence of digital osteoarthritis. DECAD is a prospective phase II trial aimed at evaluating the efficacy of surgical joint denervation in painful digital osteoarthritis.

This description comes directly from the study's public registry record.

Talk to the study team

Adeline CAMBON-BINDER, MD PhD  ·  685573795  ·  adeline.cambonbinder@aphp.fr

Jérémie SELLAM  ·  + 33 1 49 28 25 20  ·  jeremie.sellam@aphp.fr

Always discuss trial participation with your own doctor first.

Locations (1)

Rheumatology department Saint-Antoine HospitalParis, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05378841